- Tags: AMDmyopia
Pipeline
Eyconis initiates first-in-human wet AMD trial on anti-VEGF therapy
EYC-0305 is under evaluation as a potential long-acting treatment designed for 6-month or longer dosing intervals via IVT injection.
Pipeline
EyePoint’s DURAVYU delivers mixed endpoint results in first phase 3 wet AMD trial
Primary endpoint not achieved in full dataset while ad-hoc analysis excluding asymmetric cohort demonstrated non-inferiority to on-label aflibercept.
Research
Eyedaptic AI smart glasses deliver 5.7-line acuity gain in AMD
Study demonstrates significant and immediate VA improvements in patients with advanced retinal disease.
Research
NSAID use may lower AMD risk
Prescribed patients appear less likely for disease development, with the association observed across multiple AMD subtypes and several commonly used medications
Pipeline
4DMT reports new phase 2b gene therapy data for wet AMD
New 2-year data demonstrates an overall 78% treatment reduction in patients treated with 4D-150 compared to bimonthly 2 mg aflibercept.
Products
Biocon launches Eylea biosimilar to US market
With commercial rights acquired from Santen, YESAFILI (aflibercept-jbvf) is indicated for the treatment of AMD, DME, DR, and macular edema following RVO.
Research
Adverum reports 5-year extension data on wet AMD gene therapy
At ASRS 2026, the OPTIC extension finds a single Ixo-vec injection led to a 87% cumulative reduction in annualized anti-VEGF injections.
Pipeline
FDA forms advisory committee to review Sydnexis's low-dose atropine
Federal agency to discuss phase 3 clinical data supporting SYD-101 for the treatment of pediatric progressive myopia following NDA rejection.
Products
FDA approves Outlook's LYTENAVA for wet AMD
The VEGF inhibitor is now the first and only on-label ophthalmic formulation of bevacizumab for wet AMD treatment.
Research
Mediterranean diet linked to slower AMD progression
Diet aherence associated with slower AMD progression at every disease stage, with specific food components mattering most depending on the stage.
Research
New SYFOVRE data extend GA benefit to patients with concurrent wet AMD
SYFOVRE demonstrates reduced photoreceptor and RPE loss in GA patients and those with concomitant nAMD.
Pipeline
Oculgen enrolls first US patient in global phase 2/3 wet AMD trial
Company aims to utilize 36-week data from the STAT trial to support a BLA following its recent IND approval.
Pipeline
Ollin raises $330M to advance OLN324 in phase 3 studies for DME and wet AMD
Financing to support global clinical development of its bispecific antibody programs following promising phase 1b data readout in a head-to-head against faricimab.
Products
Harrow relaunches biosimilar Byooviz in the US
With commercial rights acquired from Samsung Bioepis, the FDA-approved interchangeable therapy to Lucentis is indicated for the treatment of wet AMD, RVO, and mCNV.
Pipeline
FDA accepts Outlook's fourth wet AMD BLA submission
The latest BLA package of ONS-5010 / LYTENAVA (bevacizumab-vikg) has received a PDUFA target action date for late July.
Events
The Myopia Collective adds Student Change Agent advocates to nationwide initiative
Students from the nation's top optometry school join a new cohort of Change Agents as TMC hosts first-ever Day of Advocacy during Optometry's Meeting.
Research
Atropine taper leads to less pediatric myopia progression
Long-term randomized data supports a gradual taper before discontinuation, demonstrating a reduced rebound myopia progression in children.
Research
CooperVision completes global enrollment for largest pediatric myopia control study
Post-approval studies in the U.S. and China will provide real-world evidence on the efficacy of MiSight 1 day in managing myopia.
Products
FDA approves Lupin's Lucentis biosimilar injection
Ranluspec (ranibizumab-hkdz) marks the third ranibizumab biosimilar cleared in the U.S. to treat five retinal indications.
Pipeline